AI Multitask Model for HCC Treatment

Completed

• Conditions: Hepatocellular Carcinoma (HCC)

• Registration Number: NCT07157085
• Lead Sponsor: Sun Yat-sen University

Brief Summary

We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-01
• Primary Completion: 2023-12-31
• Study Completion: 2023-12-31
• Status Verified: 2025-08
• Study First Submitted: 2025-08-28
• Study First Submitted QC: 2025-08-28
• Last Update Submitted: 2025-08-28
• Study First Posted: 2025-09-05
• Last Update Posted: 2025-09-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 7000

Inclusion Criteria

1. age 18-75 years;
2. HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria)
3. Eastern Cooperative Oncology Group performance status < 2;
4. Child-Pugh class A or B liver function;

Exclusion Criteria

1. HCC combined with other malignancies;
2. missing image data during perioperative period;
3. lost to follow-up > 12 months.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	60 months	from diagnosis of HCC to death or last follow-up

Secondary Outcome Measures

Name	Time	Method
Progression-free survival	60 months	from diagnosis of HCC to disease progression or last follow-up